MCID: GST012
MIFTS: 34

Gastroesophageal Junction Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Cardiovascular diseases

Aliases & Classifications for Gastroesophageal Junction Adenocarcinoma

MalaCards integrated aliases for Gastroesophageal Junction Adenocarcinoma:

Name: Gastroesophageal Junction Adenocarcinoma 12 14
Adenocarcinoma of the Gastroesophageal Junction 69
Adenocarcinoma of Cardioesophageal Junction 12
Adenocarcinoma of Gastroesophageal Junction 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4944
NCIt 47 C9296
UMLS 69 C1332166

Summaries for Gastroesophageal Junction Adenocarcinoma

MalaCards based summary : Gastroesophageal Junction Adenocarcinoma, also known as adenocarcinoma of the gastroesophageal junction, is related to adenocarcinoma and esophagitis, and has symptoms including abdominal pain An important gene associated with Gastroesophageal Junction Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are MAPK Pathway and Adherens junction. The drugs Herceptin and Trastuzumab have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and testes.

Related Diseases for Gastroesophageal Junction Adenocarcinoma

Diseases related to Gastroesophageal Junction Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 adenocarcinoma 10.7
2 esophagitis 10.2
3 lacrimal gland mucoepidermoid carcinoma 9.8 ERBB2 SNAI1
4 h. pylori infection 9.8
5 meningitis 9.8
6 histoplasmosis retinitis 9.5 IL1B SNAI1
7 mikulicz disease 9.5 ERBB2 IL1B
8 gallbladder cancer 9.5 ERBB2 SNAI1
9 colorectal cancer 8.4 ERBB2 GUCY2C IL1B SNAI1
10 poliomyelitis 8.0 ERBB2 GUCY2C IL1B MTA3 SNAI1

Graphical network of the top 20 diseases related to Gastroesophageal Junction Adenocarcinoma:



Diseases related to Gastroesophageal Junction Adenocarcinoma

Symptoms & Phenotypes for Gastroesophageal Junction Adenocarcinoma

UMLS symptoms related to Gastroesophageal Junction Adenocarcinoma:


abdominal pain

Drugs & Therapeutics for Gastroesophageal Junction Adenocarcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Herceptin 17 46 TRASTUZUMAB Genentech October 1998

Drugs for Gastroesophageal Junction Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903
2
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
3
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
6
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
7
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
9
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
10
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
11
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
12
Cetuximab Approved Phase 3,Phase 2 205923-56-4 56842117 2333
13
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
14
Epirubicin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 56420-45-2 41867
15
Tegafur Approved Phase 3,Phase 2,Phase 1 17902-23-7 5386
16
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
17
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
18
Ondansetron Approved Phase 3 99614-02-5 4595
19
Ranitidine Approved Phase 3 66357-59-3, 66357-35-5 3001055
20
Pertuzumab Approved Phase 2, Phase 3 145040-37-5, 380610-27-5 2540
21
Adenosine Approved, Investigational Phase 2, Phase 3 58-61-7 60961
22
Vinblastine Approved Phase 2, Phase 3 865-21-4 13342 241903
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
24
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
25
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
26
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3, Phase 1 231277-92-2, 388082-78-8 208908 9941095
27 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
28 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antimitotic Agents Phase 3,Phase 2,Phase 1
31 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
32 taxane Phase 3,Phase 2
33 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antibodies Phase 3,Phase 2,Phase 1
35 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
36 Immunoglobulins Phase 3,Phase 2,Phase 1
37 Mitogens Phase 3,Phase 2,Phase 1
38 Antidotes Phase 3,Phase 2,Phase 1
39 Micronutrients Phase 3,Phase 2,Phase 1
40 Protective Agents Phase 3,Phase 2,Phase 1
41 Trace Elements Phase 3,Phase 2,Phase 1
42 Vitamin B Complex Phase 3,Phase 2,Phase 1
43 Vitamins Phase 3,Phase 2,Phase 1
44
s 1 (combination) Phase 2, Phase 3, Phase 1
45 Angiogenesis Inhibitors Phase 2, Phase 3
46 Angiogenesis Modulating Agents Phase 2, Phase 3
47 Calcium, Dietary Phase 3,Phase 2,Phase 1
48 Analgesics Phase 3,Phase 1
49 Antiemetics Phase 3
50 Appetite Stimulants Phase 3

Interventional clinical trials:

(show top 50) (show all 261)

id Name Status NCT ID Phase Drugs
1 Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Recruiting NCT02426034 Phase 4 Apatinib
2 A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer Terminated NCT01260194 Phase 4 trastuzumab [Herceptin]
3 Impact on Quality of Life in Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction Unknown status NCT01697917 Phase 3
4 Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Unknown status NCT01015339 Phase 3 Paclitaxel;capecitabine;capecitabine;cisplatin
5 Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction Unknown status NCT01468389 Phase 3 Capecitabine;capecitabine
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
7 Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer Unknown status NCT02537171 Phase 3 apatinib
8 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed NCT00917384 Phase 3 Placebo
9 Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Completed NCT01640782 Phase 3 Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
10 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed NCT00678535 Phase 3 Cetuximab;Capecitabine;Cisplatin
11 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
12 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3 docetaxel;steroid therapy
13 Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma Completed NCT02445209 Phase 3
14 A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer Completed NCT01662869 Phase 3 5-Fluoruracil;Folinic acid;Onartuzumab;Oxaliplatin;Placebo
15 Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE- Recruiting NCT03019588 Phase 3 Paclitaxel
16 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3
17 Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction Recruiting NCT01962246 Phase 2, Phase 3 Oxaliplatin; Capecitabine
18 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Recruiting NCT02898077 Phase 3 Ramucirumab;Paclitaxel;Placebo
19 Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer Recruiting NCT01786278 Phase 2, Phase 3
20 Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Recruiting NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
21 S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients Recruiting NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
22 Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients Recruiting NCT02381847 Phase 3
23 Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer Recruiting NCT01917552 Phase 3 capecitabine
24 A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer Recruiting NCT02409199 Phase 2, Phase 3 Docetaxel;apatinib
25 Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
26 Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis Recruiting NCT02158988 Phase 3
27 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Recruiting NCT02564263 Phase 3 paclitaxel;docetaxel;irinotecan
28 Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer Recruiting NCT00450203 Phase 2, Phase 3 capecitabine;cisplatin;Epirubicin;Lapatinib
29 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Recruiting NCT03221426 Phase 3 Placebo;Cisplatin;Capecitabine;5-fluorouracil
30 A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Recruiting NCT03013010 Phase 3 Tegafur-Gimeracil-Oteracil Potassium;Oxaliplatin
31 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Recruiting NCT02625610 Phase 3 Avelumab;Oxaliplatin;5-Fluorouracil;Leucovorin;Capecitabine;Oxaliplatin;5-Fluorouracil;Leucovorin;Capecitabine
32 NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) Recruiting NCT01726452 Phase 3 Epirubicin;Cisplatin;5 Flourouracil/ Capecitabine;Paclitaxel;Carboplatin
33 FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer Recruiting NCT02581462 Phase 2, Phase 3 FLOT alone
34 Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Recruiting NCT02578368 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Trastuzumab;sodium folinate
35 Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer Recruiting NCT02512380 Phase 3 Docetaxel;oxaliplatin;s1;oxaliplatin;s1
36 Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma Recruiting NCT01404156 Phase 2, Phase 3 Epirubicin cisplatin 5-Fluorouracil
37 Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma Recruiting NCT01924819 Phase 2, Phase 3 Epirubicin + cisplatin + 5-fluorouracil
38 FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) Recruiting NCT02661971 Phase 2, Phase 3 Docetaxel;Oxaliplatin;Calciumfolinat;5-Fluorouracil
39 STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD Recruiting NCT02935881 Phase 3
40 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) Active, not recruiting NCT02370498 Phase 3 paclitaxel
41 Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Active, not recruiting NCT02545504 Phase 3 Andecaliximab;Placebo;Leucovorin;5-fluorouracil;Oxaliplatin
42 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Active, not recruiting NCT02625623 Phase 3 Avelumab;Irinotecan;Paclitaxel
43 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Active, not recruiting NCT02314117 Phase 3 Ramucirumab;Capecitabine;Cisplatin;Placebo;Fluorouracil
44 Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) Active, not recruiting NCT02494583 Phase 3 cisplatin;5-FU;capecitabine
45 A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Active, not recruiting NCT02178956 Phase 3 BBI608;Paclitaxel
46 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Active, not recruiting NCT00680901 Phase 3 Lapatinib;Placebo;Capecitabine;Oxaliplatin
47 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Active, not recruiting NCT01107639 Phase 3 cisplatin;docetaxel
48 A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma Active, not recruiting NCT01170663 Phase 3 Placebo;Paclitaxel
49 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting NCT01196390 Phase 3 Carboplatin;Paclitaxel
50 A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer Terminated NCT02137343 Phase 3 Rilotumumab;Placebo;Cisplatin;Capecitabine

Search NIH Clinical Center for Gastroesophageal Junction Adenocarcinoma

Genetic Tests for Gastroesophageal Junction Adenocarcinoma

Anatomical Context for Gastroesophageal Junction Adenocarcinoma

MalaCards organs/tissues related to Gastroesophageal Junction Adenocarcinoma:

39
Breast, Lymph Node, Testes, T Cells, Endothelial, Prostate, Bone

Publications for Gastroesophageal Junction Adenocarcinoma

Articles related to Gastroesophageal Junction Adenocarcinoma:

(show top 50) (show all 67)
id Title Authors Year
1
HER2 status in Gastric and Gastroesophageal Junction Adenocarcinoma. ( 28588175 )
2017
2
Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma. ( 28852939 )
2017
3
Significance of blood neutrophil-to-lymphocyte ratio for prognostic stratification of patients with gastroesophageal junction adenocarcinoma in the era of the 8th edition of the American Joint Committee on Cancer (AJCC8) staging. ( 28500616 )
2017
4
Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study. ( 28491144 )
2017
5
External beam radiation and high-dose-rate brachytherapy for elderly patients with gastroesophageal junction adenocarcinoma. ( 28951752 )
2017
6
HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. ( 28574779 )
2017
7
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. ( 28424936 )
2017
8
Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma. ( 28524708 )
2017
9
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. ( 26747859 )
2016
10
Central nervous system relapse in patients with untreated her2-positive esophageal or gastroesophageal junction adenocarcinoma. ( 27198655 )
2016
11
Management and Reconstruction of a Gastroesophageal Junction Adenocarcinoma Patient Three Years after Pancreaticoduodenectomy: A Surgical Puzzle. ( 27635275 )
2016
12
Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. ( 27774774 )
2016
13
Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma. ( 27065846 )
2016
14
No Survival Difference with Neaodjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base. ( 27641320 )
2016
15
Comparisons of Clinical Outcomes and Prognoses in Patients With Gastroesophageal Junction Adenocarcinoma, by Transthoracic and Transabdominal Hiatal Approaches: A Teaching Hospital Retrospective Cohort Study. ( 26683954 )
2015
16
Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma. ( 26625793 )
2015
17
Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. ( 26354521 )
2015
18
Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. ( 25753188 )
2015
19
The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy. ( 24774780 )
2014
20
Combined neutron brachytherapy with external beam radiation in patients with inoperable gastroesophageal junction adenocarcinoma. ( 25296599 )
2014
21
Personalizing risk stratification by addition of PAK1 expression to TNM staging: Improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma. ( 25159681 )
2014
22
Unanswered questions in the management of gastroesophageal junction adenocarcinoma. ( 23714486 )
2013
23
The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel. ( 23420289 )
2013
24
Distant lymph node metastases in gastroesophageal junction adenocarcinoma: impact of endoscopic ultrasound-guided fine-needle aspiration. ( 24949383 )
2013
25
Results of docetaxel plus oxaliplatin (DOCOX) A+ cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. ( 23747051 )
2013
26
HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. ( 23656792 )
2013
27
Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma. ( 24356933 )
2013
28
Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma. ( 24236193 )
2013
29
The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma. ( 23671646 )
2013
30
Gastroesophageal junction adenocarcinoma metastasizing to gingiva. ( 23776844 )
2013
31
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. ( 23921575 )
2013
32
Meningeal carcinomatosis: a metastasis from gastroesophageal junction adenocarcinoma. ( 24454393 )
2013
33
Reconstructive options for gastroesophageal junction adenocarcinoma after Roux-en-Y gastric bypass. ( 23988286 )
2013
34
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma. ( 21769462 )
2012
35
Relationship between gastroesophageal junction adenocarcinoma and Helicobacter pylori infection in Japan. ( 22472851 )
2012
36
HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. ( 21617522 )
2012
37
Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. ( 23412351 )
2012
38
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. ( 22646280 )
2012
39
Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study. ( 21063792 )
2011
40
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. ( 20574790 )
2011
41
Gastroesophageal junction adenocarcinoma of young patients who underwent curative surgery: a comparative analysis with older group. ( 21264755 )
2011
42
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. ( 20458043 )
2010
43
Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma. ( 21338186 )
2010
44
Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. ( 19267943 )
2009
45
Transition in biology and philosophy in the treatment of gastroesophageal junction adenocarcinoma. ( 19139425 )
2009
46
Local recurrence following adjuvant chemotherapy without radiotherapy in completely resected stomach and gastroesophageal junction adenocarcinoma. ( 19443416 )
2009
47
Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. ( 19487968 )
2009
48
Is radiation therapy needed in the treatment of gastroesophageal junction adenocarcinoma? ( 19343142 )
2008
49
Molecular dissection of the chromosome band 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin-dependent kinase 6 at both genomic and protein expression levels. ( 18438866 )
2008
50
Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. ( 17667920 )
2007

Variations for Gastroesophageal Junction Adenocarcinoma

Expression for Gastroesophageal Junction Adenocarcinoma

Search GEO for disease gene expression data for Gastroesophageal Junction Adenocarcinoma.

Pathways for Gastroesophageal Junction Adenocarcinoma

Pathways related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.05 ERBB2 IL1B
2 10.48 ERBB2 SNAI1

GO Terms for Gastroesophageal Junction Adenocarcinoma

Biological processes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.16 ERBB2 IL1B
2 positive regulation of epithelial to mesenchymal transition GO:0010718 8.65 SNAI1
3 regulation of ERK1 and ERK2 cascade GO:0070372 8.32 ERBB2

Sources for Gastroesophageal Junction Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....